I-Mab to Participate in September Investor Conferences
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents, has announced its participation in two major investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference from September 3-5, 2025, participating in one-on-one meetings. Additionally, I-Mab will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:30 AM ET, which will include both a company presentation and one-on-one meetings. The presentation webcast will be available on I-Mab's website for 90 days.
I-Mab (NASDAQ: IMAB), azienda biotecnologica globale con sede negli USA specializzata in agenti di immuno-oncologia di precisione, ha annunciato la sua partecipazione a due importanti conferenze per investitori a settembre 2025.
L'azienda sarà presente al Cantor Global Healthcare Conference dal 3 al 5 settembre 2025 per incontri one-to-one. Inoltre, I-Mab presenterà al H.C. Wainwright 27th Annual Global Investment Conference il 10 settembre 2025 alle 9:30 ET, con una presentazione aziendale e incontri individuali. La webcast della presentazione sarà disponibile sul sito di I-Mab per 90 giorni.
I-Mab (NASDAQ: IMAB), una compañía biotecnológica global con sede en EE. UU. especializada en agentes de inmuno-oncología de precisión, ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2025.
La compañía asistirá a la Cantor Global Healthcare Conference del 3 al 5 de septiembre de 2025, participando en reuniones one-to-one. Además, I-Mab presentará en la H.C. Wainwright 27th Annual Global Investment Conference el 10 de septiembre de 2025 a las 9:30 AM ET, con una presentación corporativa y reuniones individuales. La retransmisión web de la presentación estará disponible en la web de I-Mab durante 90 días.
I-Mab (NASDAQ: IMAB), 정밀 면역항암제 분야를 전문으로 하는 미국 소재 글로벌 바이오텍 기업이 2025년 9월에 개최되는 두 건의 주요 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 2025년 9월 3일부터 5일까지 열리는 Cantor Global Healthcare Conference에 참석해 일대일 미팅에 참여할 예정입니다. 또한 I-Mab는 2025년 9월 10일 오전 9시 30분(동부시간)에 열리는 H.C. Wainwright 27th Annual Global Investment Conference에서 회사 발표와 일대일 미팅을 진행합니다. 발표 웹캐스트는 I-Mab 웹사이트에서 90일간 시청 가능합니다.
I-Mab (NASDAQ: IMAB), une société biotechnologique mondiale basée aux États-Unis spécialisée dans les agents d'immuno-oncologie de précision, a annoncé sa participation à deux grandes conférences investisseurs en septembre 2025.
La société assistera à la Cantor Global Healthcare Conference du 3 au 5 septembre 2025, en participant à des réunions individuelles. De plus, I-Mab présentera à la H.C. Wainwright 27th Annual Global Investment Conference le 10 septembre 2025 à 9h30 ET, avec une présentation de la société et des rencontres individuelles. Le webcast de la présentation sera disponible sur le site d'I-Mab pendant 90 jours.
I-Mab (NASDAQ: IMAB), ein in den USA ansässiges globales Biotech-Unternehmen, das sich auf präzisionsbezogene Immunonkologie-Wirkstoffe spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird an der Cantor Global Healthcare Conference vom 3. bis 5. September 2025 teilnehmen und One-on-One-Gespräche führen. Zudem wird I-Mab am 10. September 2025 um 9:30 Uhr ET auf der H.C. Wainwright 27th Annual Global Investment Conference präsentieren; dies umfasst eine Unternehmenspräsentation sowie Einzelgespräche. Der Präsentations-Webcast wird für 90 Tage auf der I-Mab-Website verfügbar sein.
- None.
- None.
ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the following upcoming investor conferences in September, 2025:
Conference details are as follows:
Cantor Global Healthcare Conference
Format: One-on-one meetings
Date: September 3-5, 2025
H.C. Wainwright 27th Annual Global Investment Conference
Format: Company presentation and one-on-one meetings
Date: Wednesday, September 10, 2025
Time: 9:30 AM ET
Webcast Link: Here
The webcast of the company presentation will be accessible from News & Events page of the I-Mab website for 90 days.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.
For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn.
| I-Mab Investor & Media Contacts |
| PJ Kelleher |
| LifeSci Advisors |
| +1-617-430-7579 |
| pkelleher@lifesciadvisors.com |
| IR@imabbio.com |
FAQ
When is I-Mab (IMAB) presenting at the H.C. Wainwright Conference in September 2025?
Which investor conferences will I-Mab (IMAB) attend in September 2025?
How can investors access I-Mab's presentation at the H.C. Wainwright Conference?
What type of meetings will I-Mab participate in at the Cantor Global Healthcare Conference?
